The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...
Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...
Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
Brain tumors are abnormal growths of cells in or around the brain. They can be primary (originating in the brain) or ...
At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S ...
IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results